CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment

Rhea-AI Summary

Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 billion following an extensive evaluation by StoneBridge Advisory. This valuation underscores CBIH's strong market presence, innovative product offerings, and solid business framework. The assessment considered CBIH's financial metrics, market penetration, industry competition, and strategic planning. CBIH's team includes experts in various fields, contributing to a diversified portfolio of therapies and solutions addressing global health issues. This valuation primes CBIH for strategic alliances, investments, and expansion in the cannabis bioscience sector.

Positive

• CBIH's $2 billion valuation highlights strong market presence and solid business structure.
• StoneBridge Advisory's rigorous evaluation enhances investor and analyst confidence.
• Diversified portfolio of innovative therapies addresses global health issues.
• Valuation positions CBIH for strategic alliances, investment opportunities, and expansion.
• Expert team with diverse skill sets strengthens company’s market position.

Negative

• No specific revenue figures or profit margins disclosed in the PR.
• Valuation based on projections and strategic planning, which can be speculative.

Houston, Texas--(Newsfile Corp. - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California.

StoneBridge's assessment highlights CBIH's formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH's capacity for sustained growth and expansion.

The valuation was reached through a comprehensive review of CBIH's financial metrics, market penetration, industry competition, and strategic planning. Additionally, it took into account the exceptional skill sets within the company. Including securities attorney; corporate attorney, patent attorney, in-house counsel, comptroller with a Magister Scientiarum in Administration, CPA, PCAOB, graphic designer, Master's Degree in Audiovisual Communication and Advertising Content, Ph.D.-level scientists with emphasis on microbiology, medical professionals certified in cancer biology, peritoneal dialysis, pregnancy-related emergency care, as well as board-certified in General medicine and internal medicine, Anti-aging medicine Specialist, Master of Health Care Administration, and Doctorate in Dental Surgery. These experts have contributed to the development of a diversified portfolio of innovative therapies and medical solutions over the past 15 years. Their work addresses gaps in conventional treatments, and provides natural alternatives for widespread health issues globally.

StoneBridge Advisory employed meticulous due diligence and sophisticated financial modeling during the valuation process to guarantee precision and accurately represent the value of CBIH.

John Jones, Treasurer and Director of CBIH, commented on the significance of this valuation, stating: "We have been meticulously reconstructing our company and reinforcing its foundations. Given the promising opportunities we've identified, obtaining a valuation became the next logical step to gauge our progress and plan for future growth." He further noted, "Being positioned in rapidly evolving sectors like medical cannabis, clinical research, and biotechnology, coupled with our unparalleled expertise, positions us uniquely to seize advantageous opportunities that will benefit both our company and shareholders."

This landmark $2 Billion valuation positions CBIH among an elite group of startups and fresher/emerging companies that have achieved such a notable feat. This milestone paves the way for CBIH to pursue strategic alliances, investment opportunities, and ambitious expansion strategies, further cementing its status as a leader in the cannabis bioscience sector.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations:

East Coast

Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast

Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213088

FAQ

What is the recent valuation of CBIH?

Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 billion.

Who conducted the valuation of CBIH?

The valuation was conducted by StoneBridge Advisory, a financial advisory firm.

What factors contributed to CBIH's $2 billion valuation?

The valuation considered CBIH's financial metrics, market penetration, industry competition, and strategic planning.

What areas of expertise does CBIH's team have?

CBIH's team includes experts in law, finance, graphic design, microbiology, cancer biology, emergency care, and other medical fields.

How will the $2 billion valuation impact CBIH's future?

The valuation positions CBIH for strategic alliances, investment opportunities, and expansion in the cannabis bioscience sector.